期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 30, 期 12, 页码 891-902出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2019.08.008
关键词
-
资金
- ZONMW-VIDI grant 2013 [016.146.327]
- EU-IMI 2 (Litmus project)
- Dutch Heart Foundation CVON IN CONTROL-II grant
- ZonMW (VIDI) [016.156.445]
- EU-horizon2020 grant (Transcard)
- AMGEN
- Sanofi
- AstraZeneca
- Aegerion
- Synageva
- Gilead Research scholarship grant
- Amsterdam UMC Fellowship grant
- Holland Health TKI-PPP grant
The prevalence of non-alcoholic fatty liver disease (NAFLD) is strongly increasing and may put patients at increased risk for atherosclerotic cardiovascular disease (asCVD). Both disease phenotypes often co-occur, in the case of obesity, insulin resistance, diabetes mellitus type 2, and the metabolic syndrome. We explore the pathogenesis of NAFLD, the epidemiology of asCVD in NAFLD patients, shared drivers of both phenotypes, and factors caused by NAFLD that contribute to asCVD. Genetic studies support that NAFLD may drive asCVD through mixed hyperlipidemia. Next, we discuss the prospects of lifestyle improvement and pharmacological treatment of NAFLD for asCVD risk reduction. Finally, we point out that earlier identification of patients with NAFLD should be pursued by increasing awareness of the association of these two phenotypes and collaboration between the involved physiclans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据